Can We Treat Secondary Progressive Multiple Sclerosis Now?

Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in def...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatia, Rohit, Singh, Nishita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
View Point
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472227/
https://www.ncbi.nlm.nih.gov/pubmed/31007422
http://dx.doi.org/10.4103/aian.AIAN_345_18
_version_ 1783412204115066880
author Bhatia, Rohit
Singh, Nishita
author_facet Bhatia, Rohit
Singh, Nishita
author_sort Bhatia, Rohit
collection PubMed
description Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in defining and conducting trials in SPMS, review major clinical trials on therapies approved and unapproved in SPMS and lastly, therapies in pipeline for use in SPMS.
format Online
Article
Text
id pubmed-6472227
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-64722272019-04-19 Can We Treat Secondary Progressive Multiple Sclerosis Now? Bhatia, Rohit Singh, Nishita Ann Indian Acad Neurol View Point Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic options. This article summarizes difficulties in defining and conducting trials in SPMS, review major clinical trials on therapies approved and unapproved in SPMS and lastly, therapies in pipeline for use in SPMS. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6472227/ /pubmed/31007422 http://dx.doi.org/10.4103/aian.AIAN_345_18 Text en Copyright: © 2006 - 2019 Annals of Indian Academy of Neurology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle View Point
Bhatia, Rohit
Singh, Nishita
Can We Treat Secondary Progressive Multiple Sclerosis Now?
title Can We Treat Secondary Progressive Multiple Sclerosis Now?
title_full Can We Treat Secondary Progressive Multiple Sclerosis Now?
title_fullStr Can We Treat Secondary Progressive Multiple Sclerosis Now?
title_full_unstemmed Can We Treat Secondary Progressive Multiple Sclerosis Now?
title_short Can We Treat Secondary Progressive Multiple Sclerosis Now?
title_sort can we treat secondary progressive multiple sclerosis now?
topic View Point
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472227/
https://www.ncbi.nlm.nih.gov/pubmed/31007422
http://dx.doi.org/10.4103/aian.AIAN_345_18
work_keys_str_mv AT bhatiarohit canwetreatsecondaryprogressivemultiplesclerosisnow
AT singhnishita canwetreatsecondaryprogressivemultiplesclerosisnow

Ejemplares similares